Last updated: April 24, 2026
Who manufactures Saxenda (liraglutide) at the drug-product level?
Saxenda is marketed by Novo Nordisk and uses liraglutide, a GLP-1 receptor agonist. The drug-product supply chain is anchored in Novo Nordisk’s formulation and packaging operations and its contracted manufacturing network that produces liraglutide drug substance and the finished dose form.
Which supplier categories matter for Saxenda, and what can be tied to records?
Saxenda supply typically breaks into four supplier lanes:
1) Drug substance (liraglutide API)
- Supplier: Novo Nordisk (API supply is part of the company’s controlled manufacturing and quality system; API is not distributed as an open third-party generic commodity for branded supply contracts).
2) Drug product manufacturing (finished dose)
- Supplier: Novo Nordisk (finished-dose fill-finish and packaging are executed under Novo Nordisk manufacturing/contract manufacturing arrangements controlled through Novo Nordisk’s quality agreements).
3) Device and packaging (pen system and carton/labeling)
- Supplier: Novo Nordisk’s pen ecosystem and packaging contractors (the supply depends on the specific pen presentation and distribution region).
4) Clinical/commercial components and excipients
- Supplier: multi-tier specialty chemical and materials vendors (excipients and primary packaging materials are procured through qualified vendor systems; the named suppliers are generally not fully public at the level of a single branded product).
What does the public record typically disclose for Saxenda suppliers?
Across global drug approvals, product labeling and regulatory dossiers generally disclose:
- The marketing authorization holder (Novo Nordisk) and the manufacturing sites responsible for drug product release.
- The manufacturing responsibilities for drug substance (site of manufacture can appear in regulatory documents).
- The presence of contract manufacturing and packaging sites is often visible by named manufacturing addresses in regulatory documentation.
The most decision-grade supplier details that are routinely public are:
- Manufacturer-of-record and release sites for the finished product.
- Listed manufacturing sites for API and drug product.
Those details, however, vary by country and label version, and the same brand can show different manufacturing addresses as site transfers occur.
Where does this leave an actionable “supplier list” for Saxenda?
A complete, defensible supplier list requires mapping:
- the exact country (or label version),
- the dosage form (Saxenda is a prefilled pen),
- the manufacturing site names/addresses for both API and drug product.
Without that mapping, the only supplier that can be stated as a fact for Saxenda at the brand level is:
- Novo Nordisk (marketing authorization holder and controlling entity for the supply chain).
Decision-grade supplier roles for R&D and investment diligence
If you are performing procurement, partnering, or competitive-supply assessment, the following supplier-role structure is the actionable lens:
| Supplier lane |
What to confirm in diligence |
Typical public artifact |
| API manufacturer |
Liraglutide manufacturing site(s), change history, GMP status |
regulatory listing of API manufacturing site |
| Finished dose manufacturer |
fill-finish and release sites for prefilled pens |
regulatory listing of finished product manufacturing site |
| Primary packaging (pen) |
pen assembly manufacturer, component supply constraints |
regional dossier and device documentation |
| Secondary packaging and labeling |
carton/label vendors and compliance history by region |
packaging approvals and release documentation |
| Critical excipients and materials |
qualified supplier list for excipients used in the pen formulation |
supplier qualification packets (often not public) |
What are the high-leverage supplier risks for Saxenda that map to procurement?
For branded GLP-1 pen products, supplier concentration risk usually clusters around:
- Liraglutide API capacity (molecular complexity and fermentation/chemical synthesis constraints).
- Pre-filled pen device ecosystem (needle, reservoir, dose-metering mechanism).
- Sterile fill-finish capacity (aseptic processing windows).
- Regulatory change control (site changes require revalidation and authority submissions).
Key Takeaways
- Novo Nordisk is the controlling supplier entity for Saxenda and the marketing authorization holder.
- The publicly confirmable “supplier” information is typically the listed manufacturing sites for API and finished product, which vary by country/label version.
- For an actionable procurement or diligence supplier map, the practical path is to extract API manufacturing site and finished product fill-finish/release site from the relevant regulatory product documentation tied to the exact Saxenda presentation and region.
FAQs
1) Who makes Saxenda?
Saxenda is marketed under Novo Nordisk’s authorization; Novo Nordisk controls drug substance and drug product supply and release through its manufacturing network.
2) Can third-party suppliers manufacture Saxenda generics?
Saxenda is a branded product; third-party supply for the same label depends on contracted manufacturing for Novo Nordisk, not generic substitution.
3) Are the Saxenda pen/device manufacturers publicly named?
They can be visible in some regional technical documentation, but the degree of public disclosure varies by jurisdiction.
4) What is the most bottleneck-prone supplier lane for Saxenda?
The liraglutide API supply and the sterile fill-finish capacity for the prefilled pen presentation.
5) Do supplier lists stay constant over time?
No. Manufacturing site transfers and capacity adjustments can change listed manufacturing addresses across label versions.
References
[1] Novo Nordisk. Saxenda (liraglutide) product information and regulatory documentation (marketing authorization holder and manufacturing responsibilities).
